Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Current Investments (2016 - 2025)

United Therapeutics' Cash & Current Investments history spans 17 years, with the latest figure at $2.9 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 10.61% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, down 10.61%, while the annual FY2025 figure was $2.9 billion, 10.61% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $2.9 billion at United Therapeutics, up from $2.8 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $3.3 billion in Q3 2024 and bottomed at $1.7 billion in Q1 2021.
  • The 5-year median for Cash & Current Investments is $2.8 billion (2022), against an average of $2.7 billion.
  • The largest annual shift saw Cash & Current Investments skyrocketed 47.03% in 2022 before it fell 16.8% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $1.9 billion in 2021, then soared by 47.03% to $2.8 billion in 2022, then rose by 5.47% to $3.0 billion in 2023, then grew by 9.11% to $3.3 billion in 2024, then decreased by 10.61% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Cash & Current Investments are $2.9 billion (Q4 2025), $2.8 billion (Q3 2025), and $3.0 billion (Q2 2025).